Glaukos (NYSE:GKOS) CEO Thomas William Burns Sells 88,055 Shares

Glaukos Corporation (NYSE:GKOS) CEO Thomas William Burns sold 88,055 shares of the business’s stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $115.00, for a total value of $10,126,325.00. Following the completion of the sale, the chief executive officer directly owned 153,775 shares of the company’s stock, valued at approximately $17,684,125. The trade was a 36.41% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Thomas William Burns also recently made the following trade(s):

• On Friday, January 16th, Thomas William Burns sold 186,945 shares of Glaukos stock. The stock was sold at an average price of $115.00, for a total transaction of $21,498,675.00.

Glaukos Stock Up 2.5%

Shares of Glaukos stock traded up $2.95 during midday trading on Tuesday, reaching $123.19. 1,173,552 shares of the company’s stock traded hands, compared to its average volume of 559,549. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.47 and a current ratio of 5.20. Glaukos Corporation has a 52 week low of $73.16 and a 52 week high of $163.71. The company’s 50 day simple moving average is $108.62 and its 200 day simple moving average is $95.74. The company has a market cap of $7.08 billion, a price-to-earnings ratio of -79.99 and a beta of 0.67.

Glaukos (NYSE:GKOS) last posted its quarterly earnings data on Wednesday, October 29th. The medical instruments supplier reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.11. Glaukos had a negative return on equity of 7.52% and a negative net margin of 18.65%.The business had revenue of $133.54 million for the quarter, compared to analyst estimates of $122.55 million. During the same period in the previous year, the company posted ($0.28) earnings per share. The firm’s revenue for the quarter was up 38.1% on a year-over-year basis. Equities analysts expect that Glaukos Corporation will post -1.08 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. Truist Financial raised their target price on Glaukos from $120.00 to $145.00 and gave the company a “buy” rating in a research note on Thursday, December 18th. JPMorgan Chase & Co. boosted their price objective on Glaukos from $110.00 to $120.00 and gave the stock an “overweight” rating in a report on Thursday, October 30th. Citigroup raised their target price on shares of Glaukos from $113.00 to $125.00 and gave the company a “buy” rating in a research note on Thursday, December 11th. Wells Fargo & Company lifted their target price on shares of Glaukos from $120.00 to $122.00 and gave the stock an “overweight” rating in a report on Thursday, October 30th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $125.00 target price on shares of Glaukos in a research report on Wednesday, January 14th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $127.92.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in GKOS. Wellington Management Group LLP raised its holdings in Glaukos by 10.4% during the third quarter. Wellington Management Group LLP now owns 3,580,670 shares of the medical instruments supplier’s stock worth $292,004,000 after acquiring an additional 336,266 shares in the last quarter. Primecap Management Co. CA raised its position in Glaukos by 23.3% during the third quarter. Primecap Management Co. CA now owns 2,253,788 shares of the medical instruments supplier’s stock worth $183,796,000 after acquiring an additional 425,790 shares in the last quarter. State Street Corp lifted its stake in Glaukos by 5.3% in the second quarter. State Street Corp now owns 2,090,365 shares of the medical instruments supplier’s stock valued at $215,914,000 after acquiring an additional 105,972 shares during the last quarter. Ameriprise Financial Inc. grew its position in shares of Glaukos by 3.5% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,999,252 shares of the medical instruments supplier’s stock valued at $206,503,000 after acquiring an additional 68,497 shares during the period. Finally, Alliancebernstein L.P. increased its stake in shares of Glaukos by 38.5% during the 3rd quarter. Alliancebernstein L.P. now owns 1,733,474 shares of the medical instruments supplier’s stock worth $141,365,000 after purchasing an additional 481,620 shares during the last quarter. Institutional investors own 99.04% of the company’s stock.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.